Nuvo obtains Health Canada approval to conduct WF10 Phase 2 trial for treatment of allergic rhinitis
Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced it has received Health Canada approval to conduct a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results